Windtree Therapeutics (WINT) announces short delay in Q2 2025 10-Q

Rhea-AI Filing Summary

Windtree Therapeutics, Inc. filed a notification that it will be late in submitting its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025. The company states it cannot complete the filing on time without unreasonable effort and expense because it needs additional time to finalize its financial statements and related disclosures.

Windtree Therapeutics expects to file the Form 10-Q within five calendar days after the original due date, indicating the delay is intended to be short. The notification is signed by President and Chief Executive Officer Jed Latkin, confirming management’s authorization of this late-filing notice.

Insights

Equity research analyst

Windtree flags a short administrative delay in its Q2 10-Q.

Windtree Therapeutics reports that its Form 10-Q for the quarter ended June 30, 2025 will be filed late because it needs more time to finalize financial statements and related disclosures. The company characterizes the additional effort required as creating "unreasonable" burden under the standard that allows a brief extension.

The company expects to submit the quarterly report within five calendar days of the original deadline, which fits within the normal grace period framework. The notice does not provide quantitative results or describe specific financial issues, so the significance for the business outlook cannot be assessed from this document alone.

The filing is signed by the President and Chief Executive Officer, indicating top-level acknowledgement of the delay. Subsequent access to the completed Form 10-Q will provide the actual financial details for the quarter ended June 30, 2025.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 12b-25

NOTIFICATION OF LATE FILING

SEC FILE NUMBER

001-37392

CUSIP NUMBER

03763A207

(Check One):  ☐ Form 10-K            ☐ Form 20-F          ☐ Form 11-K          ☒ Form 10-Q          ☐ Form 10-D

                           ☐ Form N-CEN             ☐ Form N-CSR

                           For Period Ended: June 30, 2025                                       

☐ Transition Report on Form 10-K

☐ Transition Report on Form 20-F

☐ Transition Report on Form 11-K

☐ Transition Report on Form 10-Q

   For the Transition Period Ended:                                                                                           

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein

If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:              

PART I — REGISTRANT INFORMATION

Windtree Therapeutics, Inc.

Full Name of Registrant

Not Applicable

Former Name if Applicable

2600 Kelly Road, Suite 100

Address of Principal Executive Office (Street and Number)

Warrington, Pennsylvania 18976

City, State and Zip Code

PART II — RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

☒	(a)	The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
☒	(b)	The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
☒	(c)	The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III — NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

Windtree Therapeutics, Inc. (the “Company”) is unable to file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 (the “Form 10-Q”) within the prescribed time period without unreasonable effort and expense because additional time is required to finalize the Company’s financial statements and related disclosures required to be included in the Form 10-Q. The Company expects to file the Form 10-Q within five calendar days following the prescribed due date.

PART IV - OTHER INFORMATION

(1)	Name and telephone number of person to contact in regard to this notification
	Jed Latkin		(215)		488-9300
	(Name)		(Area Code)		(Telephone Number)
(2)	Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). ☒ Yes ☐ No
(3)	Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
					☐ Yes ☒ No
	If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

Windtree Therapeutics, Inc.

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date:

August 14, 2025

By:

/s/ Jed Latkin

Jed Latkin

President and Chief Executive Officer

FAQ

Why did Windtree Therapeutics (WINT) delay its June 30, 2025 Form 10-Q?

Windtree Therapeutics delayed its Form 10-Q for the quarter ended June 30, 2025 because it needs additional time to finalize its financial statements and related disclosures, and says filing on time would require unreasonable effort and expense.

How long does Windtree Therapeutics expect the Form 10-Q delay to last?

Windtree Therapeutics states that it expects to file its Form 10-Q within five calendar days following the prescribed due date for the quarter ended June 30, 2025.

What SEC form did Windtree Therapeutics file regarding the late 10-Q?

Windtree Therapeutics filed a Form 12b-25, which is a notification of late filing, covering its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.

Which period is covered by Windtree Therapeutics’ delayed Form 10-Q?

The delayed Form 10-Q from Windtree Therapeutics covers the quarter ended June 30, 2025.

Who signed Windtree Therapeutics’ late filing notification for the June 30, 2025 quarter?

The notification of late filing was signed by Jed Latkin, President and Chief Executive Officer of Windtree Therapeutics, Inc.

Does the Windtree Therapeutics late filing notice include any financial results?

The late filing notice does not provide specific financial results; it only explains that more time is needed to complete the financial statements and disclosures for the June 30, 2025 quarter.